Logo image of OTLK

OUTLOOK THERAPEUTICS INC (OTLK) Stock Fundamental Analysis

NASDAQ:OTLK - Nasdaq - US69012T3059 - Common Stock - Currency: USD

2.77  +0.43 (+18.38%)

After market: 2.92 +0.15 (+5.42%)

Fundamental Rating

1

Overall OTLK gets a fundamental rating of 1 out of 10. We evaluated OTLK against 549 industry peers in the Biotechnology industry. Both the profitability and financial health of OTLK have multiple concerns. OTLK is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

In the past year OTLK was profitable.
OTLK had a negative operating cash flow in the past year.
OTLK had negative earnings in each of the past 5 years.
In the past 5 years OTLK always reported negative operating cash flow.
OTLK Yearly Net Income VS EBIT VS OCF VS FCFOTLK Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of 108.58%, OTLK belongs to the best of the industry, outperforming 99.64% of the companies in the same industry.
Industry RankSector Rank
ROA 108.58%
ROE N/A
ROIC N/A
ROA(3y)-224.25%
ROA(5y)-230.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OTLK Yearly ROA, ROE, ROICOTLK Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K -1K

1.3 Margins

OTLK does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OTLK Yearly Profit, Operating, Gross MarginsOTLK Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -500 -1K -1.5K -2K

0

2. Health

2.1 Basic Checks

The number of shares outstanding for OTLK has been increased compared to 1 year ago.
The number of shares outstanding for OTLK has been increased compared to 5 years ago.
The debt/assets ratio for OTLK has been reduced compared to a year ago.
OTLK Yearly Shares OutstandingOTLK Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
OTLK Yearly Total Debt VS Total AssetsOTLK Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

OTLK has an Altman-Z score of -54.53. This is a bad value and indicates that OTLK is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -54.53, OTLK is not doing good in the industry: 92.90% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -54.53
ROIC/WACCN/A
WACCN/A
OTLK Yearly LT Debt VS Equity VS FCFOTLK Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

2.3 Liquidity

OTLK has a Current Ratio of 0.72. This is a bad value and indicates that OTLK is not financially healthy enough and could expect problems in meeting its short term obligations.
OTLK's Current ratio of 0.72 is on the low side compared to the rest of the industry. OTLK is outperformed by 91.62% of its industry peers.
A Quick Ratio of 0.57 indicates that OTLK may have some problems paying its short term obligations.
The Quick ratio of OTLK (0.57) is worse than 91.99% of its industry peers.
Industry RankSector Rank
Current Ratio 0.72
Quick Ratio 0.57
OTLK Yearly Current Assets VS Current LiabilitesOTLK Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

2

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 105.05% over the past year.
EPS 1Y (TTM)105.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.19%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, OTLK will show a very strong growth in Earnings Per Share. The EPS will grow by 25.95% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y54.48%
EPS Next 2Y23.89%
EPS Next 3Y32.47%
EPS Next 5Y25.95%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
OTLK Yearly Revenue VS EstimatesOTLK Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
OTLK Yearly EPS VS EstimatesOTLK Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -100 -200 -300

4

4. Valuation

4.1 Price/Earnings Ratio

A Price/Earnings ratio of 11.08 indicates a reasonable valuation of OTLK.
Based on the Price/Earnings ratio, OTLK is valued cheaper than 96.72% of the companies in the same industry.
The average S&P500 Price/Earnings ratio is at 26.82. OTLK is valued rather cheaply when compared to this.
The Forward Price/Earnings Ratio is negative for OTLK. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 11.08
Fwd PE N/A
OTLK Price Earnings VS Forward Price EarningsOTLK Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OTLK Per share dataOTLK EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1

4.3 Compensation for Growth

OTLK's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as OTLK's earnings are expected to grow with 32.47% in the coming years.
PEG (NY)0.2
PEG (5Y)N/A
EPS Next 2Y23.89%
EPS Next 3Y32.47%

0

5. Dividend

5.1 Amount

OTLK does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

OUTLOOK THERAPEUTICS INC

NASDAQ:OTLK (8/18/2025, 8:00:01 PM)

After market: 2.92 +0.15 (+5.42%)

2.77

+0.43 (+18.38%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-12 2025-08-12/bmo
Earnings (Next)12-26 2025-12-26/amc
Inst Owners16.96%
Inst Owner Change-15.7%
Ins Owners0.18%
Ins Owner Change0%
Market Cap123.04M
Analysts81.82
Price Target8.84 (219.13%)
Short Float %7.77%
Short Ratio2.36
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)112.75%
Min EPS beat(2)34.42%
Max EPS beat(2)191.08%
EPS beat(4)4
Avg EPS beat(4)108.33%
Min EPS beat(4)18.46%
Max EPS beat(4)191.08%
EPS beat(8)6
Avg EPS beat(8)42.52%
EPS beat(12)8
Avg EPS beat(12)28.88%
EPS beat(16)9
Avg EPS beat(16)14.74%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-17.46%
PT rev (3m)-17.46%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.73%
EPS NY rev (1m)0%
EPS NY rev (3m)41.81%
Revenue NQ rev (1m)58.36%
Revenue NQ rev (3m)-26.39%
Revenue NY rev (1m)15.47%
Revenue NY rev (3m)-32.15%
Valuation
Industry RankSector Rank
PE 11.08
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.25
EY9.03%
EPS(NY)-1.13
Fwd EYN/A
FCF(TTM)-1.44
FCFYN/A
OCF(TTM)-1.44
OCFYN/A
SpS0
BVpS-0.73
TBVpS-0.73
PEG (NY)0.2
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 108.58%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224.25%
ROA(5y)-230.7%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.72
Quick Ratio 0.57
Altman-Z -54.53
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)105.05%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.19%
EPS Next Y54.48%
EPS Next 2Y23.89%
EPS Next 3Y32.47%
EPS Next 5Y25.95%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-28.42%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-32.42%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-32.42%
OCF growth 3YN/A
OCF growth 5YN/A